Related Experiment Video
Updated: Jun 27, 2026
08:31
Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Delayed complete remission in a patient with multiple myeloma
R Ria1, A Vacca, G Mangialardi
1Department of Biomedical Sciences and Human Oncology, Section of Internal Medicine and Clinical Oncology, University of Bari Medical School, Bari, Italy. ria@dimo.uniba.it
European Journal of Clinical Investigation
|November 22, 2008
Summary
A 79-year-old multiple myeloma (MM) patient showed a delayed complete remission after bortezomib and pegylated liposomal doxorubicin therapy. This late response suggests potential immune and anti-angiogenic mechanisms similar to spontaneous regression in other cancers.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Multiple myeloma (MM) is a hematologic malignancy.
- Standard treatments include chemotherapy and targeted agents.
- Bortezomib and pegylated liposomal doxorubicin are used in MM treatment.
Observation:
- A 79-year-old female patient with multiple myeloma was treated with bortezomib and pegylated liposomal doxorubicin.
- The patient achieved a partial remission after eight courses of therapy.
- A complete remission was observed approximately 10 months after completion of treatment.
Findings:
- The patient exhibited a delayed, yet complete, remission from multiple myeloma.
- This response occurred significantly after the cessation of therapy.
- The observed remission may be analogous to spontaneous regression seen in other malignancies.
Implications:
- The findings suggest a potential role for immune response in delayed remission.
- Persistent anti-angiogenic effects of bortezomib might contribute to the late response.
- This case highlights the possibility of long-term remissions in multiple myeloma beyond conventional treatment timelines.
Related Concept Videos
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...